🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Compassionate Care and Organization of Healthcare Services for a Successful Transition in Rheumatology

Recruitingn/aAges 18 Years - anyAllAssistance Publique - Hôpitaux de Paris
NCT07469787 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The transition from pediatric to adult care is a critical period for young people with chronic inflammatory rheumatic diseases (CIRD) and is associated with risks of poor self-management, loss to follow-up, and disease worsening. Although structured transition programs have been recommended, real-world data on their effectiveness in rheumatology remain limited. Since 2018, a structured transition program has been implemented at Bicêtre University Hospital (AP-HP, France), combining early transition preparation, a therapeutic patient education (TPE) workshop, and a joint pediatric-adult transition consultation. Some patients benefit from both components, while others receive a transition consultation only. The BOOST-R study is a monocentric, non-interventional observational study designed to evaluate the impact of different transition modalities on self-management after transfer to adul

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age 18 years or older * Diagnosis of chronic inflammatory rheumatic disease * Previously followed in pediatric rheumatology at Bicêtre Hospital * Participation in a joint pediatric-adult transition consultation between 2018 and 2024 * Affiliated with a health insurance system * No objection expressed to participation after being informed about the study Exclusion Criteria: * Patient lost to follow-up * No participation in a joint pediatric-adult transition consultation * Patient under guardianship, curatorship, or legal protection
💊

What it tests

  • Not listed
📍

Where

1 site
CHU Bicêtre
Le Kremlin-Bicêtre, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy